聚乙二醇干扰素α-2a联合贞芪扶正颗粒治疗慢性丙型肝炎疗效观察

doi:10.3969/j.issn.1672-5069.2015.04.029

Abstract

zhu Yanfang，Gong Li，Fu Maoying. Combination of Zhenqi Fuzheng granule and peg-interferon alpha-2a in the treatment of patients with chronic hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 430-431.

References

[1] 魏来. 第46届欧洲肝病年会丙型肝炎病毒感染临床研究要点概述. 中华肝脏病杂志，2011，19（6）:412-414.
[2] 艾黎. 干扰素复合治疗慢性丙型病毒性肝炎的疗效观察. 当代医学，2010，16（16）:141.
[3] 中华医学会肝病学分会，中华医学会传染病与寄生虫病学分会. 丙型肝炎防治指南.中华传染病病杂志，2004，22（2）:131-136.
[4] 崔万善. 彩色多普勒超声评价抗病毒治疗慢性丙型肝炎的疗效. 中国老年学杂志，2012，32（22）:5033-5034.
[5] 唐武成. 干扰素、利巴韦林联合胸腺肽治疗慢性丙型肝炎的疗效分析. 实用医学杂志，2012，28（16）:2794-2795.
[6] 许英霞，陈新月，黄雁翔，等. 慢性丙型肝炎合并甲状腺功能异常回顾性分析. 北京医学，2012，34（12）:1034-1036.
[7] 任艳，郑素军，段钟平. 丙型肝炎慢性化的免疫机制研究进展. 中华肝脏病杂志，2013，21（2）:151-153.
[8] 韦新焕，马丽霞，张晶，等. 血清铁蛋白是慢性丙型肝炎患者对聚乙二醇干扰素-α和利巴韦林联合治疗应答不佳的独立预测因素. 北京医学，2012，34（12）:1088-1090.
[9] Mitchell MC，Memisoglu A，Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection.J Stud Alcohol Drugs，2012，73（6）:991-997.
[10] Lalezari J，Asmuth D，Casirb A，et a1. Short-term monotherapy with IDXl84，a liver-targeted nueleotide polymeric inhibitor，in patients with chronic hepatitis C virus infection．Antimierob Agents Chemother，2012，56（12）:6372-6378.
[11] Tsubota A，Fujise K，Namiki Y，et a1. Peginterferon and ribavirin treatment for hepatitis C virus infection．World J Gastroenterol，2011，17:419-432.
[12] Zeuzem S，Welsch C，Herrmann E. Pharmacokinetics of peginteferons． Semin Liver Dis，2003，23 （Suppl l）:23-28.
[13] 吴晓宁，彭真，贾继东. 丙型肝炎治疗及疗效判断指标进展. 中华检验医学杂志，2010，33（11）:1100-1103.
[14] 王春娟. 聚乙二醇干扰素α-2a 联合利巴韦林治疗慢性丙型肝炎临床分析. 中国误诊学杂志，2008，8（12）:2838-2839.
[15] 陈天君，Asmit Thakar，陈明伟. GP化疗联合贞芪扶正胶囊治疗NSCLC的临床观察. 时珍国医国药，2012，23:2264-2265.

Combination of Zhenqi Fuzheng granule and peg-interferon alpha-2a in the treatment of patients with chronic hepatitis C

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yuan Chunhui, Li Chunyu, Li Hongli, Zhao Hongna, Wen Wenhong, Meng Qingxu, Zhang Zhongxue. Impact of blood IL28B gene polymorphism on viralogic response in patients with HBeAg positive chronic hepatitis B receiving peginterferon alfa therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 184-187.
[2]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[3]	Wu Jing, Dong Baoji, Wu Chao. Comparison of PD-1 receptor on peripheral blood follicular helper T lymphocyte surface in chronic hepatitis C patients with low and high serum viral loads [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 192-195.
[4]	Hou Chunyang, Ma Yumei, Li Fangzhi.. Clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C and genotype one and six infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 53-56.
[5]	Wang Quanhui, Zhang Yuanhao, Yuan Shouxin, et al.. Effect of 1aparoscopic hepatectomy on peripheral blood T lymphocyte subsets and serum cytokines in patients with primary liver cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 753-756.
[6]	Song Shaotuan. Effect of paravertebral block anesthesia on circulating tumor cells and T lymphocyte subsets in patients with primary liver cancer undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 517-520.
[7]	Jiao Fangzhou, Zhang Haiyue, Zhang Wenbin, et al. Efficacy of combination sofosbuvir and pegylated interferon-α in treatment of patients with chronic hepatitis C:a Meta-analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 220-224.
[8]	Tao Guoyun, Ai Lisha, Zhang Li. Prediction of sustained virologic response by surveillance of serum ribavirin concentration in chronic hepatitis C patients with genotype 1b infection receiving standardized antiviral therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 287-288.
[9]	Zhu Chuanlong，Zhu Tiantian，Wang Kung，et al.. Serum Pygo2 levels as an indicator of liver fibrosis in patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 161-164.
[10]	Feng Xiaoxia，Nie Yuanxia，Liang Hailin.. Impact of Yiqi Jiedu Huayu compound combined with antiviral therapy on peripheral blood lymphocyte subsets and inflammatory cytokines in patients with refractory chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 674-677.
[11]	Guo Zhaoxia，Wang Yuzhen，Su Shaohui.. Prevalence of cardiovascular diseases in patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 757-761.
[12]	Zhu Fang, Yan Xuebing, Wang Jiameng, et al.. Prevalence of thyroid dysfunction and its impact on virologic response in patients with hepatitis C receiving pegylated interferon-α and ribavirin [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 540-543.
[13]	Zhu Guobing， Wu Linling， Tian Tian， et al.. Risk factors of thyroid?diseases in patients with chronic hepatitis C and hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 669-671.
[14]	Wang Zhaohui，He Changlun. Observation of three-year followed-up virologic and serological response of serum HBeAg positive patients with chronic hepatitis B receiving telbivudine treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 482-485.
[15]	Fan Jiangao. Highlights of Journal of Practical Hepatology in 2014 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 4-5.